Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

According to the median number needed to treat across the 3 analyses, an additional 8-11 individuals would need to be treated with rimegepant 75 mg to result in a comparable responder rate of at least 50% to atogepant 60 mg at week 12.

Atogepant Appears More Cost Effective and Efficacious Than Rimegepant, Indirect Comparison Data Suggests

Adaptive DBS dynamically adjusts stimulation based on patient brain activity, improving therapy customization and motor symptom management in real-time.

Medtronics’ BrainSense Adaptive DBS and Electrode Identifier Gain CE Mark Approval for Parkinson Disease

Videos

The professor in the department of diagnostic radiology at City of Hope talked about using amyloid and tau PET imaging for diagnostic clarity in Alzheimer disease, particularly in complex and atypical patient presentations. [WATCH TIME: 10 minutes]

Leveraging PET Biomarkers for Alzheimer Diagnosis in Real-World Scenarios: Phillip Kuo, MD, PhD, FACR

The newly announced sham surgery-controlled trial will include 102 patients with moderate PD testing several end points, such as change in ON-time without troublesome dyskinesia, over a 78-week period.

Cell Therapy Bemdaneprocel Advances to Phases 3 Registrational Trial in Parkinson Disease

Marco Meglio, Assistant Managing Editor for 

, has been with the team since October 2019. Follow him on Twitter 

The professor and chair of the Department of Molecular Pathobiology at NYU College of Dentistry discussed groundbreaking research on chronic pain, focusing on the discovery of new mechanisms involving nerve growth factor and its receptors.

NeuroVoices: Nigel Bunnett, PhD, BSc, on Identifying a Novel Therapeutic Target for Chronic Pain

Founding director of the Optimal Aging Institute at the NYU Grossman School of Medicine.

The founding director of the Optimal Aging Institute at the NYU Grossman School of Medicine talked about a recent study that estimated the lifetime risk of dementia and its implications for prevention, care, as well as societal planning. [WATCH TIME: 5 minutes]

Understanding Lifetime Risk and the Rising Burden of Dementia: Josef Coresh, MD, PhD

James Wheless, MD, FAAP, FAAN, FAES, Le Bonheur Chair in Pediatric Neurology at the University of Tennessee Health Science Center, shared insights on his presentation from AES 2024, focusing on stiripentol, an FDA-approved treatment for Dravet syndrome.

Optimizing Epilepsy Treatments: Stiripentol’s Role in Dravet Syndrome

, has been with the team since September 2022. Follow her on Twitter 

A duo of experts from NYU Grossman School of Medicine talked about a new study that identified deficiencies in acetyl-L-carnitine and free carnitine as potential blood biomarkers for Alzheimer disease. [WATCH TIME: 5 minutes]

Mitochondrial Molecules Linking to Alzheimer Disease Disparities in Gender: Betty Bigio, PhD; Carla Nasca, PhD

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

AES 2024

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

Alzheimer’s disease Treatment Landscape Evolutions

Emerging Agents for Treatment of Alzheimer’s Disease

Evolving Pathophysiology of Alzheimer’s Disease

Management of Alzheimer’s Disease with FDA-approved Disease-modifying Therapies

Symptom Management Agents for Patients with Alzheimer’s Disease

Lasso - DMD Peers and Perspectives NSP-21-NRD0157

 video series brings together pairs of expert clinicians and physicians to independently provide their insights on the latest and most up-to-date clinical care for specific neurologic diseases and disorders.

Emerging Agents for Treatment of Alzheimer’s Disease

EP: 1.Evolving Pathophysiology of Alzheimer’s Disease

EP: 2.Management of Alzheimer’s Disease with FDA-approved Disease-modifying Therapies

EP: 3.Emerging Agents for Treatment of Alzheimer’s Disease

EP: 4.Symptom Management Agents for Patients with Alzheimer’s Disease